登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07874282,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Histopathologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC not amenable to curative-intent therapy
入选标准第 6 条
Female study participants must be post-menopausal, surgically sterilized, or, if of child-bearing potential, have a negative serum pregnancy test within 7 days prior to the first dose, agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment, and refrain from oocyte donation and breastfeeding during this period; male study participants must agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment and refrain from sperm donation during this period
入选标准第 11 条
Received thoracic radiotherapy >30 Gy within 6 months prior to randomization; palliative local therapy for non-target lesions within 2 weeks prior to randomization; non-specific immunomodulatory therapy within 2 weeks prior to the first dose of study drug; or traditional Chinese herbal/proprietary medicine with anti-neoplastic indications within 1 week prior to randomization
排除标准第 5 条
Prior systemic anti-neoplastic therapies other than chemotherapy and PD-1/PD-L1 antibodies
排除标准第 7 条
For subjects previously exposed to PD-1/PD-L1 inhibitors: prior occurrence of immune-related adverse events (irAEs) Grade 3 or higher due to immunotherapy, irAEs leading to permanent treatment discontinuation, Grade 2 immune-related cardiac toxicity, or any-grade neurological or ocular irAEs; prior adverse events requiring immunosuppressive agents other than corticosteroids, or recurrent adverse events during prior immunotherapy requiring re-initiation of systemic corticosteroid therapy
排除标准第 14 条
Other malignancy diagnosed within 3 years prior to initiation of study drug administration
排除标准第 26 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
入选标准第 5 条
Availability of c-Met expression, PD-L1 expression and driver gene test results including at minimum EGFR and ALK for enrollment
入选标准第 9 条
At least one measurable non-cerebral lesion per RECIST v1.1
入选标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);试验排除的其他疾病;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07874282,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily agrees to participate in the study and provides signed informed consent Willing and able to comply with study and follow-up procedures Male or female, aged 18-80 years Expected survival≥3 months Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Histopathologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC not amenable to curative-intent therapy No prior systemic anti-neoplastic therapy for advanced or metastatic non-squamous NSCLC At least one measurable non-cerebral lesion per RECIST v1.1 Availability of c-Met expression, PD-L1 expression and driver gene test results including at minimum EGFR and ALK for enrollment Adequate cardiac, bone-marrow, hepatic, renal and coagulation function meeting relevant criteria Female study participants must be post-menopausal, surgically sterilized, or, if of child-bearing potential, have a negative serum pregnancy test within 7 days prior to the first dose, agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment, and refrain from oocyte donation and breastfeeding during this period; male study participants must agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment and refrain from sperm donation during this period排除标准:Exclusion Criteria:
Histologically confirmed presence of any squamous NSCLC, small-cell carcinoma, neuroendocrine carcinoma, or sarcoma component Known positive driver gene or gene mutations with approved first-line treatment options Presence of active brain metastases Screening-period imaging shows obvious tumor necrosis or cavitation, with bleeding risk upon study entry as judged by the investigator Received thoracic radiotherapy >30 Gy within 6 months prior to randomization; palliative local therapy for non-target lesions within 2 weeks prior to randomization; non-specific immunomodulatory therapy within 2 weeks prior to the first dose of study drug; or traditional Chinese herbal/proprietary medicine with anti-neoplastic indications within 1 week prior to randomization Prior immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune-cell therapy, or any other therapies targeting tumor immune mechanisms Prior systemic anti-neoplastic therapies other than chemotherapy and PD-1/PD-L1 antibodies Systemic treatment with corticosteroids or other immunosuppressive medications within 2 weeks prior to randomization Administration of any live or live-attenuated vaccine within 4 weeks prior to randomization, or planned administration of any live or live-attenuated vaccine during the study Participation in another clinical trial within 4 weeks prior to randomization Major surgery, interventional therapy, or severe trauma within 4 weeks prior to randomization, or planned major surgery during the study period; core-needle biopsy or other minor surgery within 7 days prior to the first dose History of severe coagulation disorders; or subjects receiving anticoagulant therapy, excluding prophylactic-dose anticoagulants such as low-molecular-weight heparin Toxicities from prior anti-neoplastic therapy not recovered to Grade 0-1 as defined by CTCAE v6.0; except for alopecia, pigmentation, expected irrecoverable endocrinopathies from prior immunotherapy that are stably controlled with medication, and other conditions assessed by the investigator not interfering with study drug treatment For subjects previously exposed to PD-1/PD-L1 inhibitors: prior occurrence of immune-related adverse events (irAEs) Grade 3 or higher due to immunotherapy, irAEs leading to permanent treatment discontinuation, Grade 2 immune-related cardiac toxicity, or any-grade neurological or ocular irAEs; prior adverse events requiring immunosuppressive agents other than corticosteroids, or recurrent adverse events during prior immunotherapy requiring re-initiation of systemic corticosteroid therapy Presence of severe acute or chronic infection Hemoptysis, active gastrointestinal bleeding, peptic ulcer, epistaxis, or other bleeding events requiring intervention within 4 weeks prior to randomization; or severe esophagogastric varices, vasculitis, vascular ulcer, aneurysm, or vascular dissection judged by the investigator to carry a high bleeding risk Severe arterial/venous thromboembolic events or cerebrovascular accident within 6 months prior to the first dose Active or clinically significant cardiac disease History of interstitial lung disease or pulmonary inflammation requiring systemic steroid therapy; or chest-CT at screening showing any evidence of active ILD/pulmonary inflammation, idiopathic pulmonary fibrosis, organizing pneumonia, treatment-induced pneumonitis, idiopathic pneumonia, radiation pneumonitis, severe impaired pulmonary function, or acute exacerbation of chronic obstructive pulmonary disease within 1 month prior to randomization History of gastrointestinal perforation and/or fistula, or gastrointestinal obstruction within 6 months prior to randomization Presence of systemic diseases that are not stably controlled as judged by the investigator Active autoimmune disease, or prior history of autoimmune disease with potential for recurrence Subjects with a history of other acquired or congenital immunodeficiency diseases, or history of organ transplantation Known hypersensitivity or delayed-type allergic reaction to any components of the study drug or analogous medicinal products Clinically symptomatic third-space effusion or third-space effusion requiring intervention Other malignancy diagnosed within 3 years prior to initiation of study drug administration Poor compliance; subjects expected to be unable to cooperate with completion of trial procedures Any other past or present disease, abnormal physical finding, or laboratory abnormality, in the investigator's opinion, rendering the subject unsuitable for study drug administration, likely to confound interpretation of study results, or placing the subject at high-risk Local or systemic disease not caused by malignancy, or diseases/symptoms secondary to the tumor, that may result in substantial medical risk and/or uncertainty in survival-time assessment, such as manifestations of cachexia
引自 ClinicalTrials.gov, NCT07874282, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07874282,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。